Skip to main content

Overview

My laboratory is focused on the development of imaging biomarkers for diagnosis, prognosis, staging, and therapeutic efficacy in cancer and neurologic diseases. A major emphasis of our recent activities has been the development of rapid in vivo and in vitro magnetic resonance imaging techniques at microscopic spatial resolution. Our results have been validated and applied in the study of hippocampal volume changes in the brain of genetically altered mice. The methods have allowed a non-invasive measure of small morphometric changes in the brain that present a number of advantages when compared to conventional analysis of histologic slices.

We have also developed new methods for whole-body imaging of metastatic disease in oncology. Specifically, we introduced a rapid, whole-body magnetic resonance imaging technique for leukemia and metastatic cancers including prostate and breast cancer. The method is based in part upon measurements of intracellular water self-diffusion coefficients. It requires no introduced contrast agents, can be performed in less than twenty minutes at a spatial resolution of 75 mm3, and is well suited to comparison with other whole body assays such as PET and Tc-99m bone scanning. Major applications include screening for disease, disease staging, therapeutic monitoring, and understanding the mechanisms of drug delivery. Unlike conventional bone scanning, which is an indirect measure of tumor activity, this technique is specifically sensitive to the presence of intact disease versus cells whose membranes have been compromised by cytotoxic therapy.

An area of very active research in our group at this time concerns the development of multi-component imaging biomarkers for the assessment of disease severity and therapeutic response in a uniformly fatal pediatric neurodegenerative disease known as late infantile neuronal ceroid lipofuscinosis, or Batten disease. This multidisciplinary project has a pre-clinical phase focused on the introduction of viral vector mediated gene therapy into the brain via intra-arterial delivery routes.

Finally, an important component of our research effort is devoted to hardware and software design specific to high-sensitivity image acquisition. Recently we developed a new class of high-sensitivity radiofrequency resonators for neuroimaging and magnetic resonance microscopy. In exploring the physics of these resonators it became clear that they also have applications in areas beyond biomedical imaging.

Highlights

  1. 1
    Human gene therapy · 2020
    PMID: 33233962PMCID: PMC7769048DOIFirst author36 citations
  2. 2
    Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    PMID: 40858108PMCID: PMC12432848DOIFirst author

Publications

106 publications

Active

5 grants
  • PI
    Modernization and Expansion of the Citigroup Biomedical Imaging Center at Weill Cornell Medical College
    Office of the Director, NIH · 2023–2027
    C06OD036045-01
  • KP
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2027· 2 renewals
    UL1TR002384-06
  • MPI
    Unified Shim-RF Coil Technology for Improved Whole-Brain Spectroscopic MRI for Neurological Disorders
    National Institute of Neurological Disorders and Stroke · 2024–2027
    R01NS121544-04
  • MPI
    A Self-Tuning Liquid Metal Coil Conforming to Movement for High-Resolution Brachial Plexus MRI
    National Institute of Biomedical Imaging and Bioengineering · 2022–2027
    R01EB031820-04
  • PI
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
    S10OD034271-01
Completed grants (12)
  • KP
    7T Magnetic Resonance Imaging System for Basic, Translational and Clinical Research
    Office of the Director, NIH · 2021–2025
    S10OD027039-01A1
  • MPI
    Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors
    National Institute of Biomedical Imaging and Bioengineering · 2019–2025
    R01EB027918-03
  • Co-I
    Active Contrast Encoding MRI for Breast Cancer
    National Cancer Institute · 2021–2025
    R01CA160620-08
  • PI
    BioMarin Pharmaceutical Inc. 190-203
    BioMarin Pharmaceuticals, Inc. · 2020–2024Contract
    SRA 203204-01
  • PI
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
    S10OD030447-01
  • Co-I
    Comparison of Brain Biodistribution of Two CDKL5 Gene Therapy Vector Leads
    Orphan Disease Center at University of Pennsylvania · 2021–2022
    No publications yet
    ODCUP 214052-01
  • Sub-PI
    LDN: Biomarkers for Disease Severity and Therapeutic Response in LINCL
    National Institute of Neurological Disorders and Stroke · 2009–2019 · via University of Minnesota· 2 renewals
    U54NS065768-10
  • PI
    Intra-Arterial Gene Therapy for LINCL
    National Institute of Neurological Disorders and Stroke · 2015–2018
    R56NS082655-01A1
  • KP
    Mechanisms of Recovery Following Severe Brain Injury
    Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2008–2014
    R01HD051912-05EWO
  • PI
    Small Animal 7.0 Tesla Magnetic Resonance Imaging and Spectroscopy System
    NCRR · 2007–2009 · via NIH RePORTER
    S10RR023020-01
  • PI
    MAGNETIC RESONANCE STUDIES OF BONE MARROW HEMATOPOIESIS
    NIBIB · 1994–2007 · via NIH RePORTER
    R01EB002070-09
  • PI
    MAGNETIC RESONANCE STUDIES OF BONE MARROW HEMATOPOIESIS
    NHLBI · 1994–2003 · via NIH RePORTER
    R01HL050139-08

Available technologies

Mentoring

2 mentees